Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2007

01-07-2007 | Brief Report

Cost-ineffectiveness of serum vancomycin levels

Authors: B. A. Cunha, S. S. Mohan, N. Hamid, B. P. McDermott, P. Daniels

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2007

Login to get access

Excerpt

Initial vancomycin preparations contained a variety of impurities, and early reports of “vancomycin nephrotoxicity” were apparently related to impurities in the solution and not to vancomycin per se. With improved production techniques, purified vancomycin preparations have not been associated with nephrotoxicity [1‐3]. …
Literature
1.
Kucers A, Crowe SM, Grayson ML, Hoy JF (1997) The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs, 5th edn. Butterworth-Heinemann, Oxford, UK, pp 763–790
2.
Brummett RE (1981) Effects of antibiotic–diuretic interactions in the guinea pig model of ototoxicity. Rev Infect Dis 3:S216–S223PubMed
3.
Elting LS, Rubenstein EB, Kurtin D, Rolston KV, Fangtang J, Martin CG, Raad II, Whimbey EE, Manzullo E, Bodey GP (1998) Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83:2597–2607PubMedCrossRef
4.
Appel GB, Given DB, Levine LR, Cooper GL (1986) Vancomycin and the kidney. Am J Kidney Dis 8:75–80PubMed
5.
6.
Mellor JA, Kingdom J, Cafferkey M, Keane CT (1985) Vancomycin toxicity: a prospective study. J Antimicrob Chemother 15:773–780PubMedCrossRef
7.
Moellering RC Jr (1984) Pharmacokinetics of vancomycin. J Antimicrob Chemother 14:43–52PubMed
8.
Leader WG, Chandler MH, Castiglia M (1995) Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 28:327–342PubMedCrossRef
9.
Moellering RC Jr, Krogstad DJ, Greenblatt DJ (1981) Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 94:343–346PubMed
10.
Rybak MJ, Boike SC (1986) Monitoring vancomycin therapy. Drug Intell Clin Pharm 20:757–761PubMed
11.
Cantu TG, Yamanaka-Yuen NA, Lietman PS (1994) Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 18:533–543PubMed
12.
Edwards DJ, Pancorbo S (1987) Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharm 6:652–654PubMed
13.
Moellering RC Jr (1994) Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 18:544–546PubMed
14.
Cunha BA (2004) Vancomycin serum levels: unnecessary, unhelpful and costly. Antibiotics Clinicians 8:273–277
15.
Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE (2003) Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 23:643–650PubMedCrossRef
16.
Cohen E, Dadashev A, Drucker M, Samra Z, Rubinstein E, Garty M (2002) Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 49:155–160PubMedCrossRef
Metadata
Title
Cost-ineffectiveness of serum vancomycin levels
Authors
B. A. Cunha
S. S. Mohan
N. Hamid
B. P. McDermott
P. Daniels
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2007
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0314-4

Other articles of this Issue 7/2007

European Journal of Clinical Microbiology & Infectious Diseases 7/2007 Go to the issue

Article

Evaluation of the IDI-MRSA assay on the SmartCycler real-time PCR platform for rapid detection of MRSA from screening specimens

Announcement

Announcements

Brief Report

Comparison of an automated Borrelia indirect chemiluminescent immunoassay (CLIA) with a VlsE/C6 ELISA and Immunoblot

Brief Report

Comparison of two bacteremic Asaia bogorensis isolates from Europe

Brief Report

Laboratory diagnosis of Mycoplasma pneumoniae respiratory tract infections in children

Article

Evaluation of a novel rapid one-step monoclonal chromatographic immunoassay for detection of Helicobacter pylori in stool from children
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits